Search Results
Your search for ,are matches 21909 pages
Showing 2751 - 2800Medicaid Expansion and Participation in Cancer Clinical Trials Among Patients Insured by Medicaid
Investigators may have uncovered the impact of the 2014 and 2015 Medicaid expansion on cancer clinical trial participation, according to a recent study published by Unger et al in JAMA Oncology. The new findings suggested that Medicaid expansion under the Patient Protection and Affordable Care Act...
Radiation Facility Volume and Survival in Very High–Risk Prostate Cancer Treated With Curative Radiation and Androgen-Deprivation Therapy
In a U.S. retrospective cohort study reported in JAMA Network Open, Sebastian et al found that treatment at a high-volume radiation facility was associated with improved overall survival among men with very high–risk prostate cancer receiving curative-intent radiotherapy with androgen-deprivation...
Do MDS Diagnoses Require Second Opinions?
Investigators have identified a need for strong coordination between clinicians and skilled pathologists to ensure accurate, timely diagnosis of myelodysplastic syndromes (MDS). The study findings were recently published by Gorak et al in Blood Advances. Background MDS—a collection of chronic...
Four Novel Biomarkers May Help Detect Black Patients at Risk of Advanced Prostate Cancer
Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...
Effects of BMI in Patients With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Palbociclib and Endocrine Therapy
In a preplanned analysis of the phase III PALLAS trial reported in the Journal of Clinical Oncology, Pfeiler et al found that higher body mass index (BMI) reduced the risk of neutropenia and treatment discontinuation in patients with early hormone receptor–positive breast cancer receiving adjuvant...
Diagnosing Early-Stage Bladder Cancer in Patients With Hematuria: Novel mePENK Test
Researchers have found that the new PENK methylation (mePENK) test could potentially pave the way for a breakthrough in early bladder cancer detection in patients with hematuria, according to a novel study published by Oh et al in The Journal of Molecular Diagnostics. The findings could reduce the...
PSMA PET/CT Imaging May Eliminate the Need for Preimaging Biopsy in Older Patients Undergoing Screening for Prostate Cancer
Prostate-specific membrane antigen positron-emission tomography/computed tomography (PSMA PET/CT) imaging may help physicians diagnose advanced disease and select the appropriate therapeutic interventions in patients aged 80 years or older with suspected prostate cancer, according to a recent study ...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
Expert Point of View: Michiel S. Van der Heijden, MD, PhD
Formal discussant of the CheckMate 274 trial, Michiel S. Van der Heijden, MD, PhD, of the Netherlands Cancer Institute, said it is an “important” study. “In looking at these results, one should consider the goal of adjuvant therapy in this setting. Is overtreatment of patients cured by surgery...
Expert Point of View: Daniel P. Petrylak, MD
“Clinically, the implications [of the THOR trial] are clear in that all metastatic urothelial cancers should be tested for FGFR mutations,” stated invited discussant Daniel P. Petrylak, MD, of Yale School of Medicine. “This should be done at the beginning of treatment for metastatic disease, as it...
THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Expert Point of View: Oliver Sartor, MD
The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...
PROpel Trial: Improvement in Progression-Free Survival With First-Line Olaparib Plus Abiraterone in Metastatic Prostate Cancer
The addition of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib to standard-of-care abiraterone in the first-line setting of metastatic castration-resistant prostate cancer achieved longer progression-free survival vs abiraterone alone, as demonstrated in the final results of the phase...
Three Studies From ASCO 2023 Focus on Metastatic Castration-Resistant Prostate Cancer
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
Expert Point of View: David A. Braun, MD, PhD
David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Genitourinary Oncology 2023 Almanac
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
FDA Approves Melphalan Hepatic Delivery System for Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
On August 14, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT, a melphalan hepatic delivery system, as a liver-directed treatment for adult patients with metastatic uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic...
Accelerated Approval for Elranatamab-bcmm in Patients With Relapsed or Refractory Multiple Myeloma
On August 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elranatamab-bcmm (Elrexfio), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
Expert Point of View: Mrinal S. Patnaik, MBBS
Mrinal S. Patnaik, MBBS, Chair of the Acute Leukemia and Myeloid Neoplasms Group and Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program at the Mayo Clinic, Rochester, Minnesota, offered his thoughts on the phase II study findings of ruxolitinib’s efficacy...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
Hematologic Oncology 2023 Almanac
The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...
T-Cell Tolerant Fraction May Predict Immune-Related Adverse Events Among Patients Receiving Immunotherapy
Researchers have identified a novel parameter of T cells that may help oncologists anticipate which patients are most likely to develop immunotherapy toxicity. The findings, published by Ostmeyer in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of ...
Homoharringtonine-Based Induction in Pediatric AML
In a Chinese study (CCLG-AML 2015) reported in the Journal of Clinical Oncology, Li et al found that homoharringtonine (HHT)-based induction therapy was associated with promising outcomes in pediatric acute myeloid leukemia (AML). As stated by the investigators, “HHT is commonly used for the...
Are Immune Checkpoint Inhibitors Efficacious Among Patients With Penile Squamous Cell Carcinoma?
Penile squamous cell carcinoma is a rare type of penile cancer with limited treatment options. An international study has found that the use of immune checkpoint inhibitors may offer clinical benefits for some patients with advanced penile squamous cell carcinoma. These findings were published by...
AI-Driven Muscle Mass Assessment May Aid in Detecting Sarcopenia in Patients With Head and Neck Cancer
Researchers have found a way to use artificial intelligence (AI) to diagnose sarcopenia in patients with head and neck cancer. The tool may be used to improve treatment and supportive care for patients, according to a report published by Ye et al in JAMA Network Open. “Sarcopenia is an indicator...
FDA Grants Accelerated Approval to Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma
On August 9, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific antibody talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, an...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
Susan M. Love, MD, MBA, Breast Cancer Surgeon, Researcher, and Advocate
Susan M. Love, MD, MBA, a renowned surgeon, author, researcher, and patient advocate who dedicated her life’s work to breast cancer care, died on July 2, 2023, at her home in Los Angeles. The cause of death was recurrent leukemia. She was 75. Born in Long Branch, New Jersey, on February 9, 1948,...
CAR T-Cell Therapies: Trends and Indications
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
Alcohol Consumption and Risk of Breast Cancer Recurrence
A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...
Does Daily Consumption of Sugar-Sweetened Beverages Increase the Risk of Liver Disease Among Postmenopausal Women?
Approximately 65% of adults in the United States consume sugar-sweetened beverages daily. Researchers led a study examining the associations among intake of sugar-sweetened or artificially sweetened beverages and the incidence of liver cancer and chronic liver disease mortality in a large cohort of ...
